Asset Details
Do you wish to reserve the book?
Causality of genetically determined metabolites on anxiety disorders: a two-sample Mendelian randomization study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Causality of genetically determined metabolites on anxiety disorders: a two-sample Mendelian randomization study
Do you wish to request the book?
Causality of genetically determined metabolites on anxiety disorders: a two-sample Mendelian randomization study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Causality of genetically determined metabolites on anxiety disorders: a two-sample Mendelian randomization study
2022
Overview
Background
Although anxiety disorders are one of the most prevalent mental disorders, their underlying biological mechanisms have not yet been fully elucidated. In recent years, genetically determined metabolites (GDMs) have been used to reveal the biological mechanisms of mental disorders. However, this strategy has not been applied to anxiety disorders. Herein, we explored the causality of GDMs on anxiety disorders through Mendelian randomization study, with the overarching goal of unraveling the biological mechanisms.
Methods
A two-sample Mendelian randomization (MR) analysis was implemented to assess the causality of GDMs on anxiety disorders. A genome-wide association study (GWAS) of 486 metabolites was used as the exposure, whereas four different GWAS datasets of anxiety disorders were the outcomes. Notably, all datasets were acquired from publicly available databases. A genetic instrumental variable (IV) was used to explore the causality between the metabolite and anxiety disorders for each metabolite. The MR Steiger filtering method was implemented to examine the causality between metabolites and anxiety disorders. The standard inverse variance weighted (IVW) method was first used for the causality analysis, followed by three additional MR methods (the MR-Egger, weighted median, and MR-PRESSO (pleiotropy residual sum and outlier) methods) for sensitivity analyses in MR analysis. MR-Egger intercept, and Cochran’s Q statistical analysis were used to evaluate possible heterogeneity and pleiotropy. Bonferroni correction was used to determine the causative association features (
P
< 1.03 × 10
–4
). Furthermore, metabolic pathways analysis was performed using the web-based MetaboAnalyst 5.0 software. All statistical analysis were performed in R software. The STROBE-MR checklist for the reporting of MR studies was used in this study.
Results
In MR analysis, 85 significant causative relationship GDMs were identified. Among them, 11 metabolites were overlapped in the four different datasets of anxiety disorders. Bonferroni correction showing1-linoleoylglycerophosphoethanolamine (OR
fixed-effect IVW
= 1.04; 95% CI 1.021–1.06;
P
fixed-effect IVW
= 4.3 × 10
–5
) was the most reliable causal metabolite. Our results were robust even without a single SNP because of a “leave-one-out” analysis. The MR-Egger intercept test indicated that genetic pleiotropy had no effect on the results (intercept = − 0.0013, SE = 0.0006,
P
= 0.06). No heterogeneity was detected by Cochran’s Q test (MR-Egger. Q = 7.68,
P
= 0.742; IVW. Q = 12.12,
P
= 0.436). A directionality test conducted by MR Steiger confirmed our estimation of potential causal direction (
P
< 0.001). In addition, two significant pathways, the “primary bile acid biosynthesis” pathway (
P
= 0.008) and the “valine, leucine, and isoleucine biosynthesis” pathway (
P
= 0.03
)
, were identified through metabolic pathway analysis.
Conclusion
This study provides new insights into the causal effects of GDMs on anxiety disorders by integrating genomics and metabolomics. The metabolites that drive anxiety disorders may be suited to serve as biomarkers and also will help to unravel the biological mechanisms of anxiety disorders.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
